Navigation Links
Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
Date:4/1/2008

LONDON, April 1, 2008 /PRNewswire/ -- Plethora Solutions Holdings PLC ("Plethora", AIM: PLE), the developer of specialist products for the treatment and management of urological disorders, today announced that it has entered into a revenue interest financing agreement with Paul Capital Healthcare. Through this agreement, Plethora will receive up to $28 million in cash with $15 million payable upon signature and a further $10 million upon first commercial sale of PSD502 (PLE's development stage product for the treatment of premature ejaculation) in the USA, subject to certain conditions. In return, Paul Capital Healthcare will receive an interest in the revenues generated from Plethora's male health portfolio. In addition, under certain pre-agreed conditions, Plethora will have the option to have Paul Capital Healthcare invest an amount of $3 million by way of equity subscription in 2008. The initial payment of $15 million will provide working capital to underwrite ongoing Phase III programmes in premature ejaculation and erectile dysfunction as well as strengthening the Plethora balance sheet to facilitate potential product and corporate transactions. Additional terms of the transaction are not disclosed.

The revenue interest will be paid by Plethora primarily on revenues derived from sales of ErecAid, PSD502 and PSD510. ErecAid is marketed by Plethora's subsidiary, Timm Medical, for the treatment of erectile dysfunction; while PSD502 and PSD510 are in Phase III clinical development for the treatment of premature ejaculation and erectile dysfunction respectively. Future revenues from the remainder of the existing Plethora portfolio for the treatment of female urological disorders are not covered under this agreement.

Alongside this transaction, Plethora has amended and expanded the existing convertible debt facility with ETV Capital S.A that the Company put in place in July 2007. As part of this revised arrangement, ETV Capital S.A. could potent
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
2. Pharmasset Receives $10 Million of Working Capital
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
5. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
8. AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
9. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
10. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Cranford, NJ (PRWEB) August 20, 2014 ... solutions, announced today that it has expanded its myPROpad™ ... of the EQ-5D-5L, one of the most widely ... for measuring general health status. The EQ-5D is used ... to generate a measure that can be used to ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets ... Supplies - Global Strategic Business Report" report to their offering. ... and Tissue Culture Supplies in US$ Thousands by the following Product ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . Annual ...
(Date:8/19/2014)... La Jolla, CA (PRWEB) August 19, 2014 ... the toll Parkinson’s disease can take on an individual. ... tremoring extremities, decreased facial expression, problems swallowing and severe ... due to the dying off of dopamine producing neurons ... retain themselves from a disease that slowly and progressively ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... Toronto Stock Exchange Symbol: MS , ... EDMONTON, AB , ... today announced its updated corporate strategy. The Company,s new strategy ... industry, whereby BioMS will directly invest in and advise companies ...
... , May 3 The Global Alliance for ... the 2010 BIO International Convention that they have entered into ... clinical use of drugs against tuberculosis (TB), including drug resistant ... are resistant to at least one of today,s standard first-line ...
... , WALTHAM, Mass. , May 3 Interleukin ... Lewis H. Bender will moderate and co-present a panel ... Development: How to Improve Efficacy and Commercial Success" at the BIO ... Chicago, IL.  The panel discussion will be held Wednesday, ...
Cached Biology Technology:BioMS updates corporate strategy and adds leading healthcare investment banker 2BioMS updates corporate strategy and adds leading healthcare investment banker 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 2TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 4Interleukin Genetics to Present at Upcoming Biotech Industry Meetings 2
(Date:8/21/2014)... team of researchers at Louisiana Tech University ... affordable, consumer-grade 3D printers and materials to ... antibacterial and chemotherapeutic compounds for targeted drug ... students and research faculty from Louisiana Tech,s ... to create filament extruders that can make ...
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... (HCI) at the University of Utah have identified and ... the unregulated enzyme driving the blood cancer chronic myeloid ... 6,000 new cases of CML will be diagnosed in ... inhibitors (TKIs), target BCR-ABL and are effective at controlling ... it in a way that allows patients to get ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... an iron storage molecule in the cell can serve ... gene therapy may use a technique in which non-invasive ... molecule. The results of this research, conducted by Prof. ... were published in the research journal Neoplasia. , Neeman, ...
... at Washington University in St. Louis has shown that ... sexual organs, and actually choose them for mating. That ... called a gonopodium. These fish out-compete the larger-endowed males ... burst speed than the males with larger genitalia, who ...
... show that stem cell therapy can be used effectively to ... two months, stem cells harvested from another pig's bone marrow ... and repaired damaged heart muscle by 50 percent to 75 ... the 2004 Scientific Sessions of the American Heart Association, are ...
Cached Biology News:Novel live reporting system to track cells 2IMF Launches World’s First DNA Database for Myeloma Patients 2IMF Launches World’s First DNA Database for Myeloma Patients 3IMF Launches World’s First DNA Database for Myeloma Patients 4Stem cell therapy successfully treats heart attack in animals 2
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
... HDAC4 - ChIP Grade HDAC4 is ... histone deacetylases, which consists of 1084 amino ... similar to the deacetylase domain of yeast ... the nucleus and cytoplasm in a process ...
...
Biology Products: